Sanguinarine induces apoptosis of human pancreatic carcinoma AsPC-1 and BxPC-3 cells via modulations in Bcl-2 family proteins

Cancer Letters

Volumn 249, Issue 2, 2007, Pages 198-208

  Ahsan, Haseeb ^a   Reagan Shaw, Shannon ^a   Breur, Jorien ^a   Ahmad, Nihal ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Apoptosis; Bcl 2 family proteins; Cell cycle; Pancreatic cancer; Sanguinarine

Indexed keywords

ALKALOID; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN P53; SANGUINARINE;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL VIABILITY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION;

ADENOCARCINOMA; ALKALOIDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOPHENANTHRIDINES; CARCINOMA; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; HUMANS; ISOQUINOLINES; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 33947402249     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.08.018     Document Type: Article

References (51)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., and Thun M.J. Cancer statistics, 2006. CA Cancer J. Clin. 56 (2006) 106-130
2. Fisher W.E., and Berger D.H. Angiogenesis and antiangiogenic strategies in pancreatic cancer. Int. J. Gastrointest. Cancer 33 (2003) 79-88
3. Sener S.F., Fremgen A., Menck H.R., and Winchester D.P. Pancreatic cancer: a report of treatment and survival trends for 100, 313 patients diagnosed from 1985-1995, using the National Cancer Database. J. Am. Coll. Surg. 189 (1999) 1-7
4. Gudjonsson B. Cancer of the pancreas. 50 years of surgery. Cancer 60 (1987) 2284-2303
5. Beger H.G., Rau B., Gansauge F., Poch B., and Link K.H. Treatment of pancreatic cancer: challenge of the facts. World J. Surg. 27 (2003) 1075-1084
6. Brennan M.F. Adjuvant therapy following resection for pancreatic adenocarcinoma. Surg. Oncol. Clin. N. Am. 13 (2004) 555-566 vii.
7. Wilkowski R., Thoma M., Bruns C., Duhmke E., and Heinemann V. Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer. JOP 7 (2006) 34-40
8. Mahady G.B., and Beecher C.W. Quercetin-induced benzophenanthridine alkaloid production in suspension cell cultures of Sanguinaria canadensis. Planta Med. 60 (1994) 553-557
9. Vavreckova C., Gawlik I., and Muller K. Benzophenanthridine alkaloids of Chelidonium majus; I. Inhibition of 5- and 12-lipoxygenase by a non-redox mechanism. Planta Med. 62 (1996) 397-401
10. Tandon R.K., Singh D.S., Arora R.R., Lal P., and Tandon B.N. Epidemic dropsy in New Delhi. Am. J. Clin. Nutr. 28 (1975) 883-887
11. European Pharmacopoeia. -5e. 2005. Council of Europe. Ref Type: Generic.
12. Frankos V.H., Brusick D.J., Johnson E.M., Maibach H.I., Munro I., Squire R.A., and Weil C.S. Safety of Sanguinaria extract as used in commercial toothpaste and oral rinse products. J. Can. Dent. Assoc. 56 (1990) 41-47
13. Mandel I.D. Chemotherapeutic agents for controlling plaque and gingivitis. J. Clin. Periodontol. 15 (1988) 488-498
14. Mandel I.D. Antimicrobial mouthrinses: overview and update. J. Am. Dent. Assoc. 125 Suppl 2:2S-10S (1994) 2S-10S
15. Beuria T.K., Santra M.K., and Panda D. Sanguinarine blocks cytokinesis in bacteria by inhibiting FtsZ assembly and bundling. Biochemistry %20 44 (2005) 16584-16593
16. Godowski K.C., Wolff E.D., Thompson D.M., Housley C.J., Polson A.M., Dunn R.L., Duke S.P., Stoller N.H., and Southard G.L. Whole mouth microbiota effects following subgingival delivery of sanguinarium. J. Periodontol. 66 (1995) 870-877
17. Harper D.S., Mueller L.J., Fine J.B., Gordon J., and Laster L.L. Effect of 6 months use of a dentifrice and oral rinse containing sanguinaria extract and zinc chloride upon the microflora of the dental plaque and oral soft tissues. J. Periodontol. 61 (1990) 359-363
18. Faddeeva M.D., and Beliaeva T.N. [Sanguinarine and ellipticine cytotoxic alkaloids isolated from well-known antitumor plants. Intracellular targets of their action]. Tsitologiia 39 (1997) 181-208
19. Vavreckova C., Gawlik I., and Muller K. Benzophenanthridine alkaloids of Chelidonium majus; I. Inhibition of 5- and 12-lipoxygenase by a non-redox mechanism. Planta Med. 62 (1996) 397-401
20. Wolff J., and Knipling L. Antimicrotubule properties of benzophenanthridine alkaloids. Biochemistry 32 (1993) 13334-13339
21. Vavreckova C., Ulrichova J., Hajduch M., Grambal F., Weigl E., and Simanek V. Effect of quaternary benzo[c]phenanthridine alkaloids sanguinarine, chelerythrine and fagaronine on some mammalian cells. Acta. Univ. Palacki. Olomuc. Fac. Med. 138:7-10 (1994) 7-10
22. Arnason J.T., Guerin B., Kraml M.M., Mehta B., Redmond R.W., and Scaiano J.C. Phototoxic and photochemical properties of sanguinarine. Photochem. Photobiol. 55 (1992) 35-38
23. Mitscher L.A., Park Y.H., Clark D., Clark III G.W., Hammesfahr P.D., Wu W.N., and Beal J.L. Antimicrobial agents from higher plants. An investigation of Hunnemannia fumariaefolia pseudoalcoholates of sanguinarine and chelerythrine. Lloydia 41 (1978) 145-150
24. Lenfeld J., Kroutil M., Marsalek E., Slavik J., Preininger V., and Simanek V. Antiinflammatory activity of quaternary benzophenanthridine alkaloids from Chelidonium majus. Planta Med. 43 (1981) 161-165
25. Firatli E., Unal T., Onan U., and Sandalli P. Antioxidative activities of some chemotherapeutics. A possible mechanism in reducing gingival inflammation. J. Clin. Periodontol. 21 (1994) 680-683
26. Ahmad N., Gupta S., Husain M.M., Heiskanen K.M., and Mukhtar H. Differential antiproliferative and apoptotic response of sanguinarine for cancer cells versus normal cells. Clin. Cancer Res. 6 (2000) 1524-1528
27. Adhami V.M., Aziz M.H., Reagan-Shaw S.R., Nihal M., Mukhtar H., and Ahmad N. Sanguinarine causes cell cycle blockade and apoptosis of human prostate carcinoma cells via modulation of cyclin kinase inhibitor-cyclin-cyclin-dependent kinase machinery. Mol. Cancer Ther. 3 (2004) 933-940
28. Adhami V.M., Aziz M.H., Mukhtar H., and Ahmad N. Activation of prodeath Bcl-2 family proteins and mitochondrial apoptosis pathway by sanguinarine in immortalized human HaCaT keratinocytes. Clin. Cancer Res. 9 (2003) 3176-3182
29. Weerasinghe P., Hallock S., Tang S.C., and Liepins A. Role of Bcl-2 family proteins and caspase-3 in sanguinarine-induced bimodal cell death. Cell Biol. Toxicol. 17 (2001) 371-381
30. Garcea G., Neal C.P., Pattenden C.J., Steward W.P., and Berry D.P. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur. J. Cancer. 41 (2005) 2213-2236
31. Wanebo H.J., and Vezeridis M.P. Pancreatic carcinoma in perspective. A continuing challenge. Cancer 78 (1996) 580-591
32. Duke J.A. CRC Handbook of Medicinal Herbs (1985), CRC Press, Boca Raton, FL
33. Gukovskaya A.S., and Pandol S.J. Cell death pathways in pancreatitis and pancreatic cancer. Pancreatology 4 (2004) 567-586
34. Evans J.D., Cornford P.A., Dodson A., Greenhalf W., Foster C.S., and Neoptolemos J.P. Detailed tissue expression of bcl-2, bax, bak and bcl-x in the normal human pancreas and in chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas. Pancreatology 1 (2001) 254-262
35. Magistrelli P., Coppola R., Tonini G., Vincenzi B., Santini D., Borzomati D., Vecchio F., Valeri S., Castri F., Antinori A., Nuzzo G., Caraglia M., and Picciocchi A. Apoptotic index or a combination of Bax/Bcl-2 expression correlate with survival after resection of pancreatic adenocarcinoma. J.Cell Biochem. 97 (2006) 98-108
36. Miyamoto Y., Hosotani R., Wada M., Lee J.U., Koshiba T., Fujimoto K., Tsuji S., Nakajima S., Doi R., Kato M., Shimada Y., and Imamura M. Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers. Oncology 56 (1999) 73-82
37. Brenner C., Le Bras M., and Kroemer G. Insights into the mitochondrial signaling pathway: what lessons for chemotherapy?. J. Clin. Immunol. 23 (2003) 73-80
38. Dias N., and Bailly C. Drugs targeting mitochondrial functions to control tumor cell growth. Biochem. Pharmacol. 70 (2005) 1-12
39. Kelekar A., and Thompson C.B. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol. 8 (1998) 324-330
40. Westphal S., and Kalthoff H. Apoptosis: targets in pancreatic cancer. Mol.Cancer. 2 6 (2003) 6
41. Gutierrez-Puente Y., Zapatai-Benavides P., Tari A.M., and Lopez-Berestein G. Bcl-2-related antisense therapy. Semin. Oncol. 29 (2002) 71-76
42. Hinz S., Trauzold A., Boenicke L., Sandberg C., Beckmann S., Bayer E., Walczak H., Kalthoff H., and Ungefroren H. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 19 (2000) 5477-5486
43. Hsu Y.T., Wolter K.G., and Youle R.J. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc. Natl. Acad. Sci. USA 94 (1997) 3668-3672
44. Xu Z.W., Friess H., Buchler M.W., and Solioz M. Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. Cancer Chemother. Pharmacol. 49 (2002) 504-510
45. Seki T., Ohba N., Makino R., Funatomi H., and Mitamura K. Mechanism of growth-inhibitory effect of cisplatin on human pancreatic cancer cells and status of p53 gene. Anticancer Res. 21 (2001) 1919-1924
46. Nio Y., Dong M., Iguchi C., Yamasawa K., Toga T., Itakura M., and Tamura K. Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: effects on clinical outcome and efficacy of adjuvant chemotherapy. J. Surg. Oncol. 76 (2001) 188-196
47. Nio Y., Dong M., Uegaki K., Hirahara N., Minari Y., Sasaki S., Takamura M., Iguchi C., and Tamura K. Comparative significance of p53 and WAF/1-p21 expression on the efficacy of adjuvant chemotherapy for resectable invasive ductal carcinoma of the pancreas. Pancreas. 18 (1999) 117-126
48. Dong M., Nio Y., Yamasawa K., Toga T., Yue L., and Harada T. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer. J. Surg. Oncol. 82 (2003) 111-120
49. Furuwatari C., Yagi A., Yamagami O., Ishikawa M., Hidaka E., Ueno I., Furihata K., Ogiso Y., and Katsuyama T. A comprehensive system to explore p53 mutations. Am. J. Clin. Pathol. 110 (1998) 368-373
50. Sugikawa E., Yazaki N., Tsunoda S., Nakanishi N., and Ohashi M. Inhibition of mutant p53 phosphorylation at serine 15 or serine 315 partially restores the function of wild-type p53. Biochem. Biophys. Res. Commun. 261 (1999) 256-263
51. Zerbini L.F., Wang Y., Correa R.G., Cho J.Y., and Libermann T.A. Blockage of NF-kappaB induces serine 15 phosphorylation of mutant p53 by JNK kinase in prostate cancer cells. Cell Cycle. 4 (2005) 1247-1253